Rho GTPase Transcriptome Analysis Reveals Oncogenic Roles for Rho GTPase-Activating Proteins in Basal-like Breast Cancers
Open Access
- 30 June 2016
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (13) , 3826-3837
Abstract
The basal-like breast cancer (BLBC) subtype accounts for a disproportionately high percentage of overall breast cancer mortality. The current therapeutic options for BLBC need improvement; hence, elucidating signaling pathways that drive BLBC growth may identify novel targets for the development of effective therapies. Rho GTPases have previously been implicated in promoting tumor cell proliferation and metastasis. These proteins are inactivated by Rho-selective GTPase-activating proteins (RhoGAP), which have generally been presumed to act as tumor suppressors. Surprisingly, RNA-Seq analysis of the Rho GTPase signaling transcriptome revealed high expression of several RhoGAP genes in BLBC tumors, raising the possibility that these genes may be oncogenic. To evaluate this, we examined the roles of two of these RhoGAPs, ArhGAP11A (also known as MP-GAP) and RacGAP1 (also known as MgcRacGAP), in promoting BLBC. Both proteins were highly expressed in human BLBC cell lines, and knockdown of either gene resulted in significant defects in the proliferation of these cells. Knockdown of ArhGAP11A caused CDKN1B/p27-mediated arrest in the G1 phase of the cell cycle, whereas depletion of RacGAP1 inhibited growth through the combined effects of cytokinesis failure, CDKN1A/p21-mediated RB1 inhibition, and the onset of senescence. Random migration was suppressed or enhanced by the knockdown of ArhGAP11A or RacGAP1, respectively. Cell spreading and levels of GTP-bound RhoA were increased upon depletion of either RhoGAP. We have established that, via the suppression of RhoA, ArhGAP11A and RacGAP1 are both critical drivers of BLBC growth, and propose that RhoGAPs can act as oncogenes in cancer. Cancer Res; 76(13); 3826–37. ©2016 AACR.Keywords
All Related Versions
Funding Information
- National Institutes of Health (CA042978, CA179193, and CA175747)
- National Institutes of Health (GM029860 and GM103723)
- National Institutes of Health NCI (P50-CA58223-09A1)
- Pancreatic Cancer Action Network-AACR RAN
- U.S. Army Medical Research and Materiel Command (W81XWH-14-1-0033)
This publication has 51 references indexed in Scilit:
- RacGAP1 Is a Novel Downstream Effector of E2F7-Dependent Resistance to Doxorubicin and Is Prognostic for Overall Survival in Squamous Cell CarcinomaMolecular Cancer Therapeutics, 2015
- Clinical significance of RacGAP1 expression at the invasive front of gastric cancerGastric Cancer, 2014
- Cell Cycle-Dependent Rho GTPase Activity Dynamically Regulates Cancer Cell Motility and Invasion In VivoPLOS ONE, 2013
- Upregulation of Rac GTPase-Activating Protein 1 Is Significantly Associated with the Early Recurrence of Human Hepatocellular CarcinomaClinical Cancer Research, 2011
- Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell linesBreast Cancer Research and Treatment, 2009
- Breast Tumor Kinase Phosphorylates p190RhoGAP to Regulate Rho and Ras and Promote Breast Carcinoma Growth, Migration, and InvasionCancer Research, 2008
- Chapter 14 Analysis of Low Molecular Weight GTPase Activity in Endothelial Cell Cultures2008
- GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factorsNature Reviews Molecular Cell Biology, 2005
- RhoG Signals in Parallel with Rac1 and Cdc42Journal of Biological Chemistry, 2002
- Molecular portraits of human breast tumoursNature, 2000